Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Decreasing RTX Doses are associated with Stable Disease in Patients with Multiple Sclerosis
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
9-018

To investigate the efficacy and safety of decreased dose – rituximab (RTX) maintenance therapy in multiple sclerosis (MS) patients.
RTX is an efficacious anti CD20 antibody therapy used for MS. However, data on long term treatment doses and schedule are lacking.
Prospective, 1-year, observational study. Consecutive patients with relapsing (RMS) or progressive MS (PMS) treated with repeated doses of RTX 1000 mg for ≥1 year were included and treated with RTX 500 mg every 6 months for 1 year. The proportion of patients with new T2 (NT2) and gadolinium-enhancing T1 (GAD) lesions at brain/spinal MRI at 6 and 12 months, relapses, EDSS change and adverse events, and changes in the concentration of serum neurofilament light chain (sNfL) were assessed.
59 patients were recruited (44 females, median age 50[37-57.7], 37 relapsing-remitting, 22 secondary progressive MS, disease duration 12[8–20] years, EDSS 4.0[3.0–4.5]; median RTX cumulative dose 3000[3000–4000] mg). Fifty-one and 44 patients concluded 6- and 12 months study period. Compared to baseline, 1 patient had a NT2 lesion at 6, and 1 at 12 months; no new NT2 spinal lesions at 12 months were observed. No relapses occurred, and EDSS remained stable (3.5[2.5–5.5], p=0.80 vs baseline). Median CD19 lymphocyte count was 0 (0–5.0), 1(0–15), and 0(0-4) (P=0.47), and median serum IgG were 8.8 (6.6–10.3), 7.3 (6.2–8.9), and 7.25 (6.04–8.78) at baseline, 6 ad 12 months, respectively (p=0.02). Nineteen adverse events were reported, 13 were infections, 1 was serious. Changes in the concentration of sNfL during study period will be reported.
Following repeated 1000 mg RTX doses, RTX 500 mg every 6 months was efficacious and safe in our MS population. sNfL during study period will add relevant information to our preliminary findings.
Authors/Disclosures
Claudio Gobbi, MD (Ospedale Regionale Lugano)
PRESENTER 		Dr. Gobbi has nothing to disclose.
No disclosure on file
Jens Kuhle, MD Dr. Kuhle has nothing to disclose.
No disclosure on file
Chiara Zecca, MD (Ente ospedaliero cantonale) Prof. Zecca has nothing to disclose.